Improved IBDQ at week 52 · people with active UC
Vedolizumab probably leads to higher improved IBDQ at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
SF‐36 PCS at week 6 · people with active UC
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
1 finding from 1 review
Health‐related quality of life Multiple different outcome measures used EQ‐5D and EQ‐5D VAS (9 and 26 weeks) (Batterham 2014) SF‐36 PCS and MCS (8 and 26 weeks) (Elliott 2011) · people with active UC
1 finding from 1 review
SF‐36 MCS at week 52 · people with active UC
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review
Clinical relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review